Selling a Veterinary Practice or Animal Care Business: What Buyers Evaluate

For adjacent context, compare this with Selling a Precision Machining or Metal Fabrication Business: What Buyers Evaluate and Selling an Electrical or Plumbing Contractor: M&A Issues Unique to Licensed Trades; the strongest operators connect these topics instead of treating them as separate workstreams.

Veterinary practice M&A has been one of the most active consolidation markets in the lower middle market for the past decade. The underlying dynamics are compelling: pet ownership has increased substantially, spending per pet has grown as consumers treat companion animals more like family members, and the veterinarian supply shortage has created a persistent capacity constraint that makes existing practices more valuable. The result is a buyer market where practices are frequently receiving unsolicited acquisition inquiries and trading at multiples that would have been unthinkable a decade ago.

The buyer universe is dominated by PE-backed consolidators: Mars Veterinary Health (Banfield, VCA), National Veterinary Associates (NVA), Thrive Pet Healthcare, Pathway Vet Alliance, AmeriVet, Southern Veterinary Partners, and dozens of regional platforms. These consolidators move quickly, have standardized diligence processes, and are competing actively for quality practices. For founders who understand how these buyers evaluate practices, the market presents an exceptional exit opportunity.

Selected precedent veterinary transaction markers, 2022-2026

Veterinary practice comps must separate single-site practices, multi-site groups, emergency and specialty hospitals, and DVM-dependent owner practices. Buyers pay for clinical retention, associate depth, revenue mix, and the ability to keep the medical team post-close.

Source basis: Monarch Practice Transitions 2025 veterinary M&A update, First Page Sage 2025 veterinary valuation research, and Taureau 2025 healthcare services data.

What moves the multiple

The precedent comps are useful context, but buyers do not pay the same multiple for every business in a sector. They adjust valuation based on evidence that the business can sustain earnings, transfer customer relationships, and keep operating without the founder carrying the system personally.

The practical seller objective is not to argue that the company deserves the highest public comp. It is to prove which risks do not apply, which risks have already been fixed, and which operating strengths justify the buyer moving toward the higher end of the relevant range.

DVM key-person dependency: the defining risk and how to address it

In veterinary practice M&A, the practicing veterinarian is the primary relationship asset, and the primary key-person risk. Clients choose a practice because of the specific DVM they trust with their pet's care. If the owner-DVM sells the practice and leaves, a meaningful percentage of clients will follow, not because they dislike the new owner, but because the bond with the departing veterinarian is the reason they chose the practice.

Buyers universally require post-close employment agreements from owner-DVMs as a condition of closing. The standard terms: 3–5 years of continued clinical employment, often with a compensation structure that includes base salary plus production bonus. The longer the post-close employment commitment, the more upfront cash the buyer will pay, because the DVM's continued presence de-risks the client retention assumption embedded in the purchase price.

The key-person risk is amplified when a single DVM generates 70%+ of the practice's revenue. A multi-DVM practice where the owner accounts for 40% of production is far more defensible than a solo practitioner practice where the owner is 100% of production. The preparation: if the practice is primarily solo, begin associate DVM development 24–36 months before a process, hiring and training an associate who can build their own client relationships reduces the concentration risk and makes the practice more valuable as a platform.

Associate DVM retention is also a diligence focus. Buyers will ask about the tenure, compensation, and non-compete status of every associate DVM. A practice that has cycled through 3 associates in 2 years has a retention problem that buyers will model as ongoing associate replacement cost.

Practice type and multiple framework: general, specialty, and emergency

Veterinary practices are not a single category in M&A, the practice type determines the buyer universe, the multiple, and the diligence focus.

Revenue per DVM FTE is the productivity metric that cuts across all practice types. Buyers calculate it as total practice revenue divided by the number of full-time equivalent DVMs (including owner and associates). Below $600K/FTE signals underproduction; $700K–$900K is average for a well-run general practice; above $1M/FTE signals high-efficiency production or above-market service pricing. Buyers will benchmark this against their portfolio averages and use below-benchmark productivity as a repricing argument.

Real property: owned vs. leased and the sale-leaseback decision

Veterinary practice real property, the clinic building, specialized plumbing and electrical for treatment areas, X-ray and imaging infrastructure, boarding and surgical facilities, is purpose-built and has limited alternative uses. The same own-vs.-lease considerations that apply to car washes and auto repair shops apply here.

For practice owners who own the real property: the sale-leaseback structure (selling the operating practice to a buyer while retaining the real property and leasing it back on a long-term NNN basis) is the most common structure. Consolidators actively prefer this structure because it allows them to acquire the practice without tying up capital in specialized real property. The lease economics, typically $18–35/square foot per year depending on market, provide the seller with ongoing rental income. Lease terms for veterinary practices typically run 10–15 years with renewal options.

For practice owners who lease: the same landlord consent and lease assignment mechanics apply. If the lease is within 5 years of expiration, buyers will require a lease extension as a closing condition. Veterinary leases frequently include specialized use provisions (odor control, zoning for animal care, waste disposal) that make them more complex to assign than a standard commercial lease.

Associate DVM compensation: production-based pay and EBITDA normalization

Veterinary practices compensate associate DVMs under a production-based model: typically 18–25% of collections attributable to the doctor, plus a base salary "draw" that is advanced against production and trued up quarterly or annually. The founder-DVM's compensation under this structure is almost always above a market-rate replacement cost, because founders combine the role of owner (entitled to profit distributions) and producer (entitled to production-based compensation). Separating these two components is the most important and most frequently mishandled normalization in veterinary M&A.

The normalization question: if the selling founder-DVM is the practice's primary producer, their compensation must be normalized to the fully-loaded cost of a market-rate associate DVM replacement — typically $130,000–$185,000 total compensation for a general practice associate in most U.S. markets in 2024, inclusive of base salary, production bonus, benefits, CE allowance, and malpractice insurance. Under-replacing this cost (normalizing to $90,000 because "we'll find a good new grad") overstates EBITDA and creates post-close disputes when the new associate's actual cost exceeds the normalized assumption.

Relief DVM usage — contract DVMs who work part-time to fill schedule gaps — is a cost that varies significantly by month and by season. A practice with high relief DVM usage in its busiest months is effectively converting fixed staffing cost to variable, which can look favorable in a given month's EBITDA but overstates normalized profitability. Buyers will ask for monthly relief DVM spend for 24 months and will normalize EBITDA using average relief cost, not the lowest month.